Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

BackgroundGemtuzumab ozogamicin (GO), one of the first targeted drugs used in oncology, consists of an anti-cluster of differentiation 33 (CD33) monoclonal antibody bound to a derivative of cytotoxic calicheamicin. After the drug withdrawn in 2010 due to a significantly higher rate of early deaths,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Katarzyna Pawinska-Wasikowska, Malgorzata Czogala, Szymon Skoczen, Marta Surman, Monika Rygielska, Teofila Ksiazek, Agnieszka Pac, Aleksandra Wieczorek, Jolanta Skalska-Sadowska, Magdalena Samborska, Jacek Wachowiak, Radoslaw Chaber, Renata Tomaszewska, Tomasz Szczepanski, Karolina Zielezinska, Tomasz Urasinski, Malgorzata Moj-Hackemer, Krzysztof Kalwak, Marta Kozlowska, Ninela Irga-Jaworska, Walentyna Balwierz, Karolina Bukowska-Strakova
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-12-01
Colecção:	Frontiers in Immunology
Assuntos:	acute myeloid leukemia gemtuzumab ozogamicin relapse refractory children immunotherapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268993/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!